Asset profile
CID-103
Monoclonal antibody
Evidence outlook · lead readout
NCT04758767 · Multiple Myeloma
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04758767: All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. The primary goal was tracking adverse events, not disease response, and results are not yet posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.